Mushroom Beta-Glucans: How They Train Antiviral Immunity

Medicinal Mushrooms as Antivirals

2026 RCT

The first randomized clinical trial to test polypore mushroom mycelia alongside COVID-19 vaccination, published in BMC Immunology, brings decades of beta-glucan antiviral research to a human clinical endpoint.

Saxe et al., BMC Immunology, 2026

4

antiviral compound classes identified in medicinal mushrooms

Triple helix

structural form that gives lentinan its antiviral potency

2026

first human RCT testing mushroom mycelia alongside a COVID vaccine

Saxe et al., BMC Immunology, 2026

View as image ↗

Most supplements work through a single mechanism: they provide a nutrient, block an enzyme, or briefly spike one immune marker. Mushroom beta-glucans do something more unusual, and the immunological research on it has become genuinely interesting over the past decade. These polysaccharides appear to reprogram immune cells at a molecular level, generating a mushroom beta-glucan antiviral immune response that persists long after the supplement is gone. The phenomenon has a name in immunology: trained immunity.

The science goes further than vague "immune support" claims. A 2021 systematic review by Seo and Choi in Viruses documented four compound classes in medicinal mushrooms, each blocking different steps in the viral life cycle at the same time.^[1] And in 2026, a randomized clinical trial tested whether polypore mushroom mycelium could improve antibody responses to a COVID-19 vaccine. That trial is the most rigorous human test of mushroom antiviral immune support published so far.^[4]

This article covers the specific mechanisms by which beta-glucans activate antiviral immunity, why the structural form of a beta-glucan determines its potency, and what the latest clinical research suggests. For the broader landscape of mushroom antiviral compounds beyond beta-glucans, see the full antiviral mushroom overview and the pillar article on beta-glucans.

Why Beta-Glucans Aren't Simply "Immune Boosters"

The phrase "immune booster" has been applied to so many supplements that it carries almost no information anymore. For beta-glucans specifically, the label undersells the actual mechanism considerably.

When beta-glucans from medicinal mushrooms enter the body, they are recognized by a receptor on the surface of macrophages and monocytes. Macrophages and monocytes are the immune cells that serve as first responders when viruses invade tissue. That receptor is called dectin-1. Binding to dectin-1 triggers a signaling cascade through two pathways, NF-kB and MAPK, that do not just temporarily activate those cells. They appear to alter which genes the cells express going forward.

The result is what immunologists call trained immunity: macrophages and monocytes that have encountered beta-glucans respond more vigorously the next time they detect a viral signal, even without any further beta-glucan exposure. The effect is epigenetic, meaning it changes gene expression in the cell without altering the underlying DNA sequence. Trained macrophages produce more interferon, a signaling protein that alerts neighboring cells to viral invasion and slows viral replication. They also prime natural killer cells, the immune cells that patrol the body and eliminate cells that have already been infected by a virus.

Seo and Choi's 2021 review in Viruses mapped how this trained immunity mechanism differs from what vaccines do.^[1] Vaccines train the adaptive immune system: they create memory T cells and B cells that recognize one specific virus or antigen. Beta-glucan training operates in the innate immune system, the faster, non-specific branch that fires first. It does not target any particular virus. What it does is improve the speed and strength of the broad antiviral response that activates before specific antibodies can be deployed. That is a different and complementary mechanism, not a competing one.

This distinction is what led researchers to ask whether mushroom beta-glucans might enhance vaccines rather than replace them. If trained innate immunity fires faster, the window when a virus can replicate unchecked before specific antibodies arrive could be meaningfully shorter. That hypothesis has now been tested in a clinical trial.

Same Mushroom, Completely Different Immune Effects: Murphy's 2020 Discovery

The assumption underlying most beta-glucan marketing is that beta-glucans are one thing: more of them means more immune support. Murphy and colleagues published a study in 2020 that complicates this picture significantly.^[2]

They took shiitake mushrooms (Lentinus edodes) and extracted different beta-glucan fractions from the same source material, varying particle size, molecular weight, and the branching architecture of each polysaccharide chain. Then they tested each fraction in cell culture conditions designed to be relevant to COVID-19 respiratory damage.

What they found: fractions from the same mushroom produced entirely different immune effects.

Some fractions preferentially activated natural killer cells, the cells that patrol the body and destroy virus-infected tissue before infection can spread. Other fractions provided what the researchers called pulmonary cytoprotection. In plain terms: these fractions shielded lung tissue from the kind of inflammatory damage that makes respiratory viral infections dangerous.

Both are antiviral effects, but through different mechanisms, serving different phases of an infection. The NK cell effect is relevant to early viral containment. The lung-protective effect is relevant to the inflammatory damage that accumulates during and after active replication.

Murphy's team specifically titled the paper with COVID-19 implications. Severe COVID-19 involves two waves of damage: direct viral injury to lung cells, then the immune system's inflammatory response to that damage, which in serious cases causes more harm than the virus itself. A beta-glucan fraction that specifically protects lung tissue from this inflammatory response is a distinct mechanism from NK cell activation, operating at a different point in the disease process.

The implication the paper established is that extraction method determines which immune pathway gets activated. A high-molecular-weight fraction that activates NK cells and one that provides lung protection may require different processing approaches to preserve their specific structures. This means that two products with identical labeled beta-glucan percentages could produce substantially different biological effects depending on how they were extracted.

Most beta-glucan supplement research ignores this entirely. The assumption that "more beta-glucan = more immune support" does not account for fraction composition.

The Triple Helix That Gives Lentinan Its Antiviral Potency

Lentinan is the specific beta-glucan most associated with shiitake mushrooms, and it is one of the most studied mushroom polysaccharides in antiviral research. Ren and colleagues conducted a detailed structural characterization in 2018 and demonstrated why the molecular architecture of a beta-glucan matters for what it does biologically.^[3]

The key structural feature is the triple helix. Lentinan's backbone is a chain of glucose molecules connected by beta-1,3 bonds. This type of bond, unlike the bonds that hold starch together, resists human digestive enzymes, which is why lentinan reaches immune cells intact rather than being broken down in the gut. The backbone chain is also decorated with branches at every sixth glucose unit, connected by 1,6 bonds.

Under the right conditions, three of these chains wind around each other to form a triple helix. Think of it as three strands of rope twisted together rather than lying flat.

Ren's team showed that this triple-helix conformation is specifically linked to antiviral potency. Lentinan in triple-helix form produced significantly stronger antiviral effects against a test virus than lentinan whose structure had been disrupted. When processing conditions unwind the triple helix into a random coil or a flat single chain, the result is a structurally different molecule. It still contains the same glucose units with the same bonds, but it behaves differently in immune assays.

This finding has a direct practical implication for how beta-glucan products are made. Hot water extraction, the method used in traditional mushroom teas and modern aqueous extraction, preserves the triple-helix structure. Alcohol extraction does not, because beta-glucans are not soluble in alcohol. High-temperature industrial spray drying and some chemical modification processes disrupt the helical conformation. The extraction method listed on a product label reflects, indirectly, whether the beta-glucan structure that showed antiviral activity in Ren's research is likely to be intact.

Ren's characterization work used Lentinus edodes mycelia specifically: the dense, root-like underground structures rather than the fruiting body (the cap and stem of the mushroom). Both mycelium and fruiting body contain lentinan, but mycelium can be grown year-round in controlled conditions, which is why it has become the preferred substrate for commercial beta-glucan production. This matters for the next section, because the 2026 clinical trial used polypore mycelia as its experimental material.

A 2026 RCT Tests Beta-Glucans Alongside a COVID Vaccine

The trained immunity hypothesis produces a specific, testable prediction: if beta-glucan training strengthens the innate immune response, and if the innate response helps amplify the adaptive response after vaccination, then taking mushroom beta-glucans around the time of vaccination should improve the resulting antibody levels.

Saxe and colleagues ran the direct test of this prediction and published the results in BMC Immunology in 2026.^[4] In a randomized clinical trial, participants who supplemented with polypore mushroom mycelia alongside COVID-19 vaccination were compared to controls who received the vaccine alone. The primary outcome was the antibody response generated.

Polypore mushrooms include turkey tail (Trametes versicolor), reishi (Ganoderma lucidum), chaga (Inonotus obliquus), and related bracket-fungi species. They are particularly dense in beta-glucans and have the longest research history for antiviral properties among medicinal mushrooms. Using them as a vaccine adjuvant, a substance that enhances the immune response to a vaccine, represents the translation of decades of preclinical antiviral research into a controlled clinical endpoint.

The Saxe 2026 trial is the most rigorous human study of mushroom antiviral immune support published so far. It tests a specific and plausible question, not whether mushrooms alone fight viruses, which is difficult to measure in a controlled trial, but whether mushroom compounds produce a measurable improvement in the immune response to a known antigen under controlled conditions. That is a tractable clinical question, and this is the first RCT to answer it with mushroom mycelia.

For more depth on this trial and the broader research context for COVID-19 and influenza, see the dedicated article on mushrooms and antiviral defense from influenza to SARS-CoV-2.

What Trained Immunity Does (and Does Not) Protect Against

It is worth being precise about what beta-glucan-trained antiviral immunity does and does not do. The trained immunity concept is powerful, but it can be misread.

Trained innate immunity does not create lasting protection against a specific virus the way antibodies from vaccines or prior infection do. What it does is prime the cells that mount the first response to any viral intrusion: macrophages that detect foreign particles and produce interferon, natural killer cells that identify and destroy infected tissue, and the dendritic cells that eventually hand the alarm signal off to the adaptive immune system.

These cells are not virus-specific. They respond to general viral signatures rather than the surface proteins of a particular strain. Their advantage is speed: where adaptive immunity takes days to weeks to produce targeted antibodies, innate immune cells respond within hours.

This matters because the window in which the innate response can contain a viral infection before it becomes systemic is short, often 24 to 72 hours after initial exposure. If trained immunity means macrophages and NK cells respond faster and more vigorously in that window, the viral load at the point when adaptive immunity engages may be substantially lower. That is the antiviral benefit that preclinical beta-glucan research demonstrates repeatedly, and that the 2026 vaccine trial approaches from the angle of a measurable clinical endpoint.

What trained immunity does not do: it does not generate neutralizing antibodies against specific strains, it does not provide the durable antigen-specific memory that allows the adaptive immune system to eliminate a previously-encountered virus within days, and it is not a treatment for established infections in the way antiviral drugs are.

The article on mushrooms and influenza covers how the timing of supplementation affects which mechanisms are active, and why the distinction between direct antiviral effects and immunomodulatory preparation requires different approaches depending on whether you are trying to prevent infection or limit severity. For research on mushroom antiviral effects against specific viruses including hepatitis B and C, see the hepatitis antiviral research review.

Why Extraction Method and Structure Matter Practically

The research covered in this article points to one conclusion that most beta-glucan product marketing does not address: the structural form and fraction composition of a beta-glucan product affect which immune pathways it activates.

Extraction method. Hot water extraction, also called aqueous extraction, preserves the triple-helix structure characterized by Ren et al. and is the format validated across most antiviral beta-glucan research. Dual-extract products combine hot water (for beta-glucans) and alcohol (for terpenoids and ganoderic acids) extractions. Simple grinding of dried mushroom into powder without extraction produces a product whose beta-glucan content may be present but not necessarily bioavailable in triple-helix form.

Source material. Both mushroom fruiting bodies and mycelium contain beta-glucans, though the proportions differ by species and growth conditions. The 2026 clinical trial used polypore mycelia; Ren's lentinan characterization used shiitake mycelia. Neither source is inherently superior, but the source affects what the product contains and how it compares to specific studies.

Standardized beta-glucan percentage. Products standardized to a specific beta-glucan content, typically 20 to 40 percent for extracts, provide more predictable dosing than unstandardized powders where the actual beta-glucan level can vary widely. The published research does not establish a universal minimum effective dose for antiviral immune effects, because study designs have used different species, forms, and dose ranges.

Species. The beta-glucan structures in shiitake (lentinan), turkey tail (PSK, PSP), reishi, and chaga are distinct. They share the beta-1,3 backbone but differ in their branching patterns and molecular weights. The 2026 RCT used polypore species rather than shiitake, and the mechanism details may differ somewhat across species even when both are classified as "beta-glucans."

For a deeper exploration of how beta-glucans reprogram immune cells at the epigenetic level beyond acute activation, see the dedicated article on how beta-glucans epigenetically reprogram immune cells.

The Bottom Line

The antiviral immune effects of mushroom beta-glucans operate through trained immunity, an epigenetic reprogramming of macrophages and natural killer cells that produces sustained antiviral readiness rather than temporary stimulation. Murphy et al. (2020) demonstrated that different beta-glucan fractions from the same mushroom activate entirely different immune pathways, including NK cell stimulation and pulmonary cytoprotection relevant to respiratory viral infections. Ren et al. (2018) established that the triple-helix structure of lentinan is the key determinant of antiviral potency, a finding with direct implications for extraction method and product quality. The 2026 RCT by Saxe et al. in BMC Immunology is the first controlled human study of mushroom mycelia as a vaccine adjuvant, bringing the trained immunity hypothesis to a clinical test. The picture is substantially more nuanced than "beta-glucans boost immunity": extraction method, molecular structure, and fraction composition each affect which immune pathways are activated.

Frequently Asked Questions

How do beta-glucans help fight viruses?

Beta-glucans from medicinal mushrooms bind to dectin-1 receptors on macrophages and monocytes, triggering trained immunity: a persistent state of enhanced antiviral readiness in which these immune cells respond more vigorously to viral signals for weeks to months. Different beta-glucan fractions also activate natural killer cells that destroy virus-infected tissue and provide pulmonary protection relevant to respiratory infections. Seo and Choi's 2021 systematic review in Viruses documented the full mechanism map across four antiviral compound classes found in mushrooms, with beta-glucans as the most studied polysaccharide class.

Do beta-glucans boost antiviral immunity?

The evidence for beta-glucan antiviral immune activation is strongest in preclinical research, where the trained immunity mechanism is well-documented at the cellular level. A 2026 randomized clinical trial (Saxe et al., BMC Immunology) tested polypore mushroom mycelia alongside COVID-19 vaccination, the most rigorous human study of whether beta-glucan immune training produces measurably better vaccine antibody responses. In cell culture, Murphy et al. (2020) showed that specific shiitake beta-glucan fractions stimulate NK cell activity and protect lung tissue from viral-induced inflammatory damage.

What beta-glucan mushrooms are best for viral immunity?

Polypore mushrooms, including turkey tail (Trametes versicolor), reishi (Ganoderma lucidum), and chaga (Inonotus obliquus), have the broadest antiviral research base and were the species used in the 2026 COVID vaccine adjuvant clinical trial. Shiitake (Lentinus edodes) is the source of lentinan, the most structurally characterized antiviral beta-glucan. Species choice is secondary to extraction method and structural integrity: hot water extraction preserving the triple-helix conformation is the format consistently used in antiviral research.

How do beta-glucans activate NK cells?

Beta-glucans bind to dectin-1 receptors on macrophages and monocytes, triggering NF-kB and MAPK signaling pathways that increase interferon production and enhance natural killer cell activity. NK cells are the immune cells that patrol tissue and eliminate cells that have been infected by a virus, before the infection spreads further. Murphy et al. (2020) showed that specific high-molecular-weight shiitake beta-glucan fractions preferentially activate this NK cell pathway compared to other fractions from the same mushroom, suggesting that fraction composition rather than total beta-glucan quantity determines this specific effect.

What is trained immunity from beta-glucans?

Trained immunity is an epigenetic phenomenon in which macrophages and monocytes that have encountered beta-glucans undergo gene expression changes that persist for weeks to months after exposure ends. Unlike adaptive immunity, which creates memory for specific antigens after infection or vaccination, trained immunity is non-specific: it enhances the innate immune response to any viral signal, not only the pathogen the cell previously encountered. The practical implication is that the antiviral benefit of beta-glucans does not require continuous supplementation; it reflects durable cellular reprogramming rather than acute, time-limited stimulation.

Sources & References

1. 1RTHM-00717·Seo, Dong Joo et al. (2021). “Antiviral Bioactive Compounds of Mushrooms and Their Antiviral Mechanisms: A Review..” Viruses.Study breakdown →PubMed →↩
2. 2RTHM-00638·Murphy, Emma J et al. (2020). “β-Glucan extracts from the same edible shiitake mushroom Lentinus edodes produce differential in-vitro immunomodulatory and pulmonary cytoprotective effects - Implications for coronavirus disease (COVID-19) immunotherapies..” The Science of the total environment.Study breakdown →PubMed →↩
3. 3RTHM-00528·Ren, Guangming et al. (2018). “Structural characterization and antiviral activity of lentinan from Lentinus edodes mycelia against infectious hematopoietic necrosis virus..” International journal of biological macromolecules.Study breakdown →PubMed →↩
4. 4RTHM-02244·Saxe, Gordon et al. (2026). “Polypore mushroom mycelia as an adjunct to COVID-19 vaccination: a randomized clinical trial..” BMC immunology.Study breakdown →PubMed →↩